RS55342B1 - Derivati 8-karbamoil-2-(2,3-disupstituisanog pirid-6-il)-1,2,3,4-tetrahidroizohinolina kao sredstva za indukovanje apoptoze za lečenje karcinoma i imunskih i autoimunskih bolesti - Google Patents
Derivati 8-karbamoil-2-(2,3-disupstituisanog pirid-6-il)-1,2,3,4-tetrahidroizohinolina kao sredstva za indukovanje apoptoze za lečenje karcinoma i imunskih i autoimunskih bolestiInfo
- Publication number
- RS55342B1 RS55342B1 RS20160954A RSP20160954A RS55342B1 RS 55342 B1 RS55342 B1 RS 55342B1 RS 20160954 A RS20160954 A RS 20160954A RS P20160954 A RSP20160954 A RS P20160954A RS 55342 B1 RS55342 B1 RS 55342B1
- Authority
- RS
- Serbia
- Prior art keywords
- carbamoyl
- apoptosis
- immune
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547162P | 2011-10-14 | 2011-10-14 | |
| CN2012079012 | 2012-07-23 | ||
| PCT/US2012/059720 WO2013055897A1 (en) | 2011-10-14 | 2012-10-11 | 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP12780605.7A EP2766361B1 (en) | 2011-10-14 | 2012-10-11 | 8-carbamoyl-2-(2,3-disubstituted pyrid-6-yl)-1,2,3,4-tetrahydroisoquinoline derivatives as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55342B1 true RS55342B1 (sr) | 2017-03-31 |
Family
ID=47116421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160954A RS55342B1 (sr) | 2011-10-14 | 2012-10-11 | Derivati 8-karbamoil-2-(2,3-disupstituisanog pirid-6-il)-1,2,3,4-tetrahidroizohinolina kao sredstva za indukovanje apoptoze za lečenje karcinoma i imunskih i autoimunskih bolesti |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP2766361B1 (sr) |
| JP (2) | JP6155270B2 (sr) |
| KR (1) | KR102019643B1 (sr) |
| AR (1) | AR088327A1 (sr) |
| AU (2) | AU2012322698A1 (sr) |
| BR (1) | BR112014009053B1 (sr) |
| CA (1) | CA2851364C (sr) |
| CL (1) | CL2014000905A1 (sr) |
| CO (1) | CO6950476A2 (sr) |
| CR (2) | CR20200097A (sr) |
| CY (1) | CY1118224T1 (sr) |
| DK (1) | DK2766361T3 (sr) |
| DO (2) | DOP2014000070A (sr) |
| EC (1) | ECSP14000357A (sr) |
| ES (1) | ES2598877T3 (sr) |
| GT (1) | GT201400064A (sr) |
| HK (1) | HK1200167A1 (sr) |
| HR (1) | HRP20161319T1 (sr) |
| HU (1) | HUE030589T2 (sr) |
| IL (1) | IL231856A (sr) |
| LT (1) | LT2766361T (sr) |
| ME (1) | ME02514B (sr) |
| MX (1) | MX356031B (sr) |
| PE (1) | PE20141282A1 (sr) |
| PH (1) | PH12015501498B1 (sr) |
| PL (1) | PL2766361T3 (sr) |
| PT (1) | PT2766361T (sr) |
| RS (1) | RS55342B1 (sr) |
| RU (1) | RU2625315C2 (sr) |
| SG (1) | SG11201401279XA (sr) |
| SI (1) | SI2766361T1 (sr) |
| TW (1) | TWI571466B (sr) |
| UA (1) | UA115042C2 (sr) |
| UY (1) | UY34382A (sr) |
| WO (1) | WO2013055897A1 (sr) |
| ZA (1) | ZA201402556B (sr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| US20160339117A1 (en) * | 2014-12-09 | 2016-11-24 | Abbvie Inc. | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same |
| JP2018506509A (ja) * | 2014-12-09 | 2018-03-08 | アッヴィ・インコーポレイテッド | 細胞透過性Ｂｃｌ−ｘＬ阻害剤との抗体薬物コンジュゲート |
| WO2016094517A1 (en) * | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds and antibody drug conjugates including the same |
| CN104473923B (zh) * | 2014-12-29 | 2016-08-17 | 巩春智 | 一种防治慢性心力衰竭的药物组合物及其应用 |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| EP3888689A1 (en) * | 2016-06-08 | 2021-10-06 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
| CA3027047A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| MX2018015280A (es) * | 2016-06-08 | 2019-08-12 | Abbvie Inc | Conjugados de anticuerpo y farmaco anti-egfr. |
| AU2017277914A1 (en) * | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
| US20200147235A1 (en) * | 2016-06-08 | 2020-05-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| RS61828B1 (sr) | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
| JP2019521106A (ja) * | 2016-06-08 | 2019-07-25 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| WO2018092064A1 (en) * | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019178433A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer |
| AR119494A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS |
| KR20230143605A (ko) | 2020-11-24 | 2023-10-12 | 노파르티스 아게 | Bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4288434A1 (en) | 2021-02-02 | 2023-12-13 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
| US20230390404A1 (en) * | 2022-05-06 | 2023-12-07 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| WO2023215449A1 (en) * | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| WO2023236814A1 (zh) * | 2022-06-10 | 2023-12-14 | 成都先导药物开发股份有限公司 | 一种化合物及其在制备bcl-xl抑制剂中的用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| AU6964096A (en) | 1995-09-15 | 1997-04-01 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone n-oxides |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| BR0112395A (pt) * | 2000-06-21 | 2003-07-08 | Hoffmann La Roche | Derivados de benzotiazol |
| US20060052382A1 (en) | 2002-12-20 | 2006-03-09 | Duffy Joseph L | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| ES2525229T3 (es) | 2007-02-15 | 2014-12-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolinas como ligandos de TAAR1 |
| EP2148867B1 (en) | 2007-04-19 | 2014-09-10 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| MX2011006514A (es) * | 2008-12-19 | 2011-10-11 | Inst Medical W & E Hall | Compuesto y metodo de uso. |
| JP5770102B2 (ja) * | 2008-12-19 | 2015-08-26 | ジェネンテック， インコーポレイテッド | 複素環化合物と使用方法 |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2012
- 2012-10-08 TW TW101137131A patent/TWI571466B/zh active
- 2012-10-10 UY UY0001034382A patent/UY34382A/es unknown
- 2012-10-11 KR KR1020147012846A patent/KR102019643B1/ko active IP Right Grant
- 2012-10-11 BR BR112014009053-0A patent/BR112014009053B1/pt active IP Right Grant
- 2012-10-11 LT LTEP12780605.7T patent/LT2766361T/lt unknown
- 2012-10-11 JP JP2014535869A patent/JP6155270B2/ja active Active
- 2012-10-11 ME MEP-2016-227A patent/ME02514B/me unknown
- 2012-10-11 SG SG11201401279XA patent/SG11201401279XA/en unknown
- 2012-10-11 PT PT127806057T patent/PT2766361T/pt unknown
- 2012-10-11 MX MX2014004556A patent/MX356031B/es active IP Right Grant
- 2012-10-11 UA UAA201405089A patent/UA115042C2/uk unknown
- 2012-10-11 DK DK12780605.7T patent/DK2766361T3/en active
- 2012-10-11 CA CA2851364A patent/CA2851364C/en active Active
- 2012-10-11 RU RU2014119250A patent/RU2625315C2/ru active
- 2012-10-11 WO PCT/US2012/059720 patent/WO2013055897A1/en active Application Filing
- 2012-10-11 SI SI201230730A patent/SI2766361T1/sl unknown
- 2012-10-11 PL PL12780605T patent/PL2766361T3/pl unknown
- 2012-10-11 ES ES12780605.7T patent/ES2598877T3/es active Active
- 2012-10-11 EP EP12780605.7A patent/EP2766361B1/en active Active
- 2012-10-11 CR CR20200097A patent/CR20200097A/es unknown
- 2012-10-11 AU AU2012322698A patent/AU2012322698A1/en not_active Abandoned
- 2012-10-11 HU HUE12780605A patent/HUE030589T2/en unknown
- 2012-10-11 PE PE2014000506A patent/PE20141282A1/es active IP Right Grant
- 2012-10-11 RS RS20160954A patent/RS55342B1/sr unknown
- 2012-10-12 AR ARP120103811A patent/AR088327A1/es active IP Right Grant
-
2014
- 2014-04-01 IL IL231856A patent/IL231856A/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02556A patent/ZA201402556B/en unknown
- 2014-04-09 DO DO2014000070A patent/DOP2014000070A/es unknown
- 2014-04-10 CL CL2014000905A patent/CL2014000905A1/es unknown
- 2014-04-10 GT GT201400064A patent/GT201400064A/es unknown
- 2014-05-06 CR CR20140205A patent/CR20140205A/es unknown
- 2014-05-07 CO CO14097093A patent/CO6950476A2/es unknown
- 2014-05-08 EC ECIEPI2014357A patent/ECSP14000357A/es unknown
-
2015
- 2015-01-16 HK HK15100555.0A patent/HK1200167A1/zh unknown
- 2015-06-30 PH PH12015501498A patent/PH12015501498B1/en unknown
-
2016
- 2016-10-11 HR HRP20161319TT patent/HRP20161319T1/hr unknown
- 2016-10-27 CY CY20161101096T patent/CY1118224T1/el unknown
-
2017
- 2017-04-19 JP JP2017082912A patent/JP6395893B2/ja active Active
- 2017-07-20 AU AU2017206246A patent/AU2017206246B2/en active Active
-
2019
- 2019-02-01 DO DO2019000022A patent/DOP2019000022A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200167A1 (zh) | 作為用於治療癌症和免疫性和自身免疫性疾病的凋亡誘導劑的 -氨基甲酰基- -二取代吡啶- -基 -四氫異喹啉衍生物 | |
| HK1210156A1 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| HK1210030A1 (en) | Sulfamoyl aryamides and the use thereof as medicaments for the treatment of hepatitis b | |
| HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| HK1177201A1 (zh) | 治療癌症和免疫疾病的作為 -選擇性細胞凋亡誘導劑的磺酰胺衍生物 | |
| HK1220324A1 (zh) | 用於治療血管緊張素相關疾病的方法、化合物和組合物 | |
| TWI561521B (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| AP2014007804A0 (en) | Compositions and methods for the treatment of hepatic diseases and disorders. | |
| PL3466425T3 (pl) | Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych | |
| HK1192726A1 (en) | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5- | |
| HK1209426A1 (zh) | 培美曲塞及其賴氨酸鹽的製備方法 | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| PT2981518T (pt) | Um processo melhorado para a preparação de maleato de fluvoxamina | |
| PL2837632T3 (pl) | Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych | |
| IL236870B (en) | History of hydroxystatin for the treatment of osteoarthritis | |
| PL399423A1 (pl) | Sposób wytwarzania 2'-hydroksydihydrochalkonu | |
| PL399422A1 (pl) | Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu | |
| PL398695A1 (pl) | Sposób wytwarzania 2'-hydroksydihydrochalkonu | |
| PL395184A1 (pl) | Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu | |
| TH137287B (th) | สารชักนำอะพอพโทซิสสำหรับการรักษามะเร็งและโรคทางภูมิคุ้มกันและภูมิต้าน ตนเอง (Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases) |